Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-90
SponsorThe Cooper Health System

About this trial

This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

undergoing robotic wedge resection or lobectomy for lung mass(es)

Disqualifiers

emergency case

history of opiate abuse

chronic pain syndrome

intravenous drug use

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intercostal nerve block and wound infiltration with liposomal bupivacaine

    Drug

    Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.

  • Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone

    Drug

    Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.

Treatment groups

34 Participants
are divided into 2 treatment groups
Group A: Bupivacaine/epinephrine + dexamethasoneExperimental treatment 1 intervention
Group B: Liposomal bupivacaineActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Visual Analogue Scale pain scores

Visual Analogue Scale (VAS) pain score will be assessed for non-inferiority of bupivacaine/epinephrine +dexamethasone vs. liposomal bupivacaine. A non-inferiority margin of 2 points on the VAS scale will be considered non-inferior.

Time frame
24 hours post-surgery

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.